Crossref
Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial
AME Clinical Trials Review · 2026-04 · 4 · 21-21
DOI: 10.21037/actr-26-0007 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Michael Wang und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Wang, M., Neuenburg, J. K., & Tam, C. S. (2026). Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review, 4, 21-21. https://doi.org/10.21037/actr-26-0007
Vancouver
Wang M, Neuenburg JK, Tam CS. Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial. AME Clinical Trials Review. 2026;4:21-21. doi:10.21037/actr-26-0007
BibTeX
@article{Wang2026,
author = {Wang, Michael and Neuenburg, Jutta K. and Tam, Constantine S.},
title = {Reply to: Ibrutinib plus venetoclax for patients with relapsed or refractory mantle cell lymphoma: an editorial on the phase 3 SYMPATICO trial},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {21--21},
doi = {10.21037/actr-26-0007}
}
EUVIMED